BiotechTube

Ravulizumab

Pre-clinicalRecruiting
0 watching 0 views this week💤 Quiet
23
Hype Score

Development Stage

1
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Atypical Hemolytic Uremic Syndrome

Conditions

Atypical Hemolytic Uremic Syndrome

Trial Timeline

Apr 1, 2026 → Dec 31, 2030

NCT ID
NCT07399730

About Ravulizumab

Ravulizumab is a pre-clinical stage product being developed by AstraZeneca for Atypical Hemolytic Uremic Syndrome. The current trial status is recruiting. This product is registered under clinical trial identifier NCT07399730. Target conditions include Atypical Hemolytic Uremic Syndrome.

Hype Score Breakdown

Clinical
5
Activity
2
Company
10
Novelty
2
Community
1

Clinical Trials (3)

NCT IDPhaseStatus
NCT07399730Pre-clinicalRecruiting
NCT06909253Pre-clinicalRecruiting
NCT06633536Pre-clinicalActive

Competing Products

18 competing products in Atypical Hemolytic Uremic Syndrome

See all competitors
ProductCompanyStageHype Score
CrovalimabChugai PharmaceuticalPhase 3
77
CrovalimabChugai PharmaceuticalPhase 3
77
DuloxetineEli LillyApproved
85
Teriparatide 20 mcgEli LillyPhase 3
77
BaricitinibEli LillyPre-clinical
23
EculizumabAstraZenecaPhase 3
77
IptacopanNovartisPhase 3
77
Iptcaopan 200 mgNovartisPhase 3
77
IptacopanNovartisPhase 3
77
Ropeginterferon Alfa-2BPharmaEssentiaPhase 2
51
CCX168AmgenPhase 2
51
Tazemetostat + Nivolumab + IpilimumabBristol Myers SquibbPhase 1/2
40
CemdisiranAlnylam PharmaceuticalsPhase 2
49
cemdisiran + PlacebosAlnylam PharmaceuticalsPhase 2
49
Axatilimab + AzacitidineIncytePhase 1/2
38
Gemcitabine + PaxalisibPacific BiosciencesPhase 2
44
Apatinib MesylateBrain BiotechPre-clinical
15
azurin-derived cell-penetrating peptide p28Brain BiotechPhase 1
25

Other Products from AstraZeneca

QuetiapineApproved
85
Dapagliflozin 5 mg + Placebo tabletApproved
85
QuetiapineApproved
85
Ticagrelor + ClopidogrelApproved
85
DurvalumabApproved
85